Aligos Therapeutics, Inc. is experiencing a notable uptick in its stock price following the announcement of inducement grants under Nasdaq listing rules. On December 13, 2024, the company disclosed that its Compensation Committee granted a non-qualified stock option to purchase 5,500 shares to a newly hired employee. This grant, part of Aligos' 2024 Inducement Plan, is intended to attract new talent and is structured to vest over four years, with 25% vesting after the first year and the remainder vesting monthly. Such announcements can often signal confidence in the company's future prospects and may be perceived positively by investors.
Aligos Therapeutics, Inc. (ALGS) is currently trading at $35.56, reflecting a 7.40% increase from its previous close of $33.11.